AAV9 Vectors for Sustained Cardiac Natriuretic Peptide Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular and renal diseases, particularly hypertension, are inadequate in effectively managing hypertensive heart disease and cardiac function, leading to increased morbidity and mortality.
Innovation Solution
The use of adeno-associated virus serotype 9 (AAV9) vectors designed to express natriuretic polypeptides, such as atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), which are administered to deliver sustained expression of these peptides to cardiac cells, reducing blood pressure and improving cardiac function without toxicological effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for hypertension, then blood pressure can be reduced to some extent, but the effectiveness in managing hypertensive heart disease and cardiac function is inadequate
Solution Approach 1:
The patent uses AAV9 vectors as an intermediary delivery system to transport natriuretic polypeptide genes into cardiac cells. This viral vector mediator enables sustained expression of therapeutic peptides directly in the heart, overcoming the limitations of conventional systemic treatments that fail to achieve adequate cardiac-specific therapeutic levels.
Solution Approach 2:
The patent changes the parameter of drug delivery from intermittent systemic administration to sustained local expression. By using AAV9-mediated gene transfer, the therapeutic natriuretic polypeptides are continuously produced within cardiac cells, maintaining therapeutic levels and improving reliability of hypertension and heart disease management.
2Reliability
If sustained expression of natriuretic polypeptides is achieved through gene therapy, then blood pressure reduction and cardiac function improvement are enhanced, but the complexity of the treatment increases
Solution Approach 1:
The AAV9 vector system enables self-service by autonomously delivering and expressing the therapeutic gene within target cells. Once the vector infects cardiac cells, the cells themselves produce the natriuretic polypeptides continuously, eliminating the need for ongoing external administration and reducing long-term treatment complexity.
Solution Approach 2:
The AAV9 vector serves multiple functions: it acts as a delivery vehicle, integrates the therapeutic gene, and enables sustained expression. This multi-functional approach consolidates what would otherwise require multiple separate treatment components into a single therapeutic agent, managing complexity while maintaining reliability.
3Reliability
If natriuretic polypeptides are delivered to cardiac cells, then left ventricular function is improved, but potential toxicological effects and tolerance development may occur
Solution Approach 1:
The patent applies local quality by targeting natriuretic polypeptide expression specifically to cardiac cells through AAV9-mediated gene delivery. This localized expression ensures therapeutic benefits are concentrated where needed in the heart while minimizing systemic exposure and potential toxicological effects on other organs.
Solution Approach 2:
The patent converts the potential harm of viral vector delivery into benefit by using AAV9, which has demonstrated safety and immunogenicity advantages over other viral vectors. The initial concern about viral toxicity is transformed into a benefit through AAV9's unique properties of low pathogenicity and sustained transgene expression without integration into host genome.
Data Source
AI summary
This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.